Literature DB >> 6853034

Absorption of oral vancomycin - possible associated toxicity.

C M Thompson, S S Long, P H Gilligan, J W Prebis.   

Abstract

We report a case of an anephric child who accumulated significant concentrations of vancomycin during oral therapy for Clostridium difficile pseudomembranous colitis. Sustained serum vancomycin levels of 34 microgram/ml and CSF level of 4.2 microgram/ml were documented during an unexplained clinical syndrome of fever and encephalopathy. Discontinuation of drug and performance of hemodialysis reduced serum concentrations to 24 microgram/ml and were associated with rapid resolution of symptoms. Patients with renal impairment and intestinal disease who receive oral vancomycin may absorb and accumulate significant amounts of drug.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6853034

Source DB:  PubMed          Journal:  Int J Pediatr Nephrol        ISSN: 0391-6510


  11 in total

1.  Vancomycin in resistant hepatic encephalopathy.

Authors:  A Forbes; I Murray-Lyon
Journal:  Gut       Date:  1990-12       Impact factor: 23.059

Review 2.  Pharmacokinetics and administration regimens of vancomycin in neonates, infants and children.

Authors:  K A Rodvold; J A Everett; R D Pryka; D M Kraus
Journal:  Clin Pharmacokinet       Date:  1997-07       Impact factor: 6.447

3.  A Prospective Pilot Study on the Systemic Absorption of Oral Vancomycin in Children With Colitis.

Authors:  James W Antoon; Margaret Hall; Diana Metropulos; Michael J Steiner; Ravi Jhaveri; Jacob A Lohr
Journal:  J Pediatr Pharmacol Ther       Date:  2016 Sep-Oct

Review 4.  Does oral vancomycin use necessitate therapeutic drug monitoring?

Authors:  Nevio Cimolai
Journal:  Infection       Date:  2019-11-11       Impact factor: 3.553

5.  Oral Absorption of Enteral Vancomycin in a Child with Clostridium difficile Colitis and Renal Impairment.

Authors:  Adam Wood; Katie Wassil; Elisa Edwards
Journal:  J Pediatr Pharmacol Ther       Date:  2013-10

6.  Pharmacokinetics of LFF571 and vancomycin in patients with moderate Clostridium difficile infections.

Authors:  Suraj G Bhansali; Kathleen Mullane; Lillian S L Ting; Jennifer A Leeds; Kristina Dabovic; Jens Praestgaard; Peter Pertel
Journal:  Antimicrob Agents Chemother       Date:  2014-12-22       Impact factor: 5.191

Review 7.  Clinical pharmacokinetics of vancomycin.

Authors:  G R Matzke; G G Zhanel; D R Guay
Journal:  Clin Pharmacokinet       Date:  1986 Jul-Aug       Impact factor: 6.447

8.  Oral vancomycin hydrochloride therapy for postoperative methicillin-cephem-resistant Staphylococcus aureus enteritis.

Authors:  T Konishi; Y Idezuki; H Kobayashi; K Shimada; S Iwai; K Yamaguchi; N Shinagawa
Journal:  Surg Today       Date:  1997       Impact factor: 2.540

9.  The Effects of Fasting and Massive Diarrhea on Absorption of Enteral Vancomycin in Critically Ill Patients: A Retrospective Observational Study.

Authors:  Takehiko Oami; Noriyuki Hattori; Yosuke Matsumura; Eizo Watanabe; Ryuzo Abe; Taku Oshima; Waka Takahashi; Shingo Yamazaki; Tatsuya Suzuki; Shigeto Oda
Journal:  Front Med (Lausanne)       Date:  2017-06-08

10.  An elderly woman with 'Red Man Syndrome' in association with oral vancomycin therapy: a case report.

Authors:  Phillippa Bailey; Henry Gray
Journal:  Cases J       Date:  2008-08-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.